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Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107 S87(range, 1.0-8.0). Three-year non-relapse mortality for all pts
was 7% (0% for PETD-neg vs. 12% for PETD-pos, p¼0.1). Pre-
HCT PETD-neg status remained prognostic for improved 3-
yr OS (HR¼0.1; 95% CI, 0-0.86) and lower relapse risk
(HR¼0.34; 95% CI, 0.1-1.0) in the multivariable Cox models.
Conclusions: Our study demonstrates encouraging out-
comes achieved with NMA allo-HCT in heavily pre-treated
pts (3-yr OS, PFS and relapse of 72% [95% CI, 54%-84%], 40%
[95% CI, 24%-55%], 48% [95% CI, 29%-66%], respectively). FDG-
PET imaging interpreted by Deauville criteria can serve as a
powerful prognostic tool in pts with RR HL considered for
NMA allo-HCT.83
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Adult T-cell leukemia/lymphoma (ATLL), which is a human
T-lymphotropic virus type I (HTLV-1)-related hematological
malignancy, is known as a poorly prognostic disease even
with the intensive chemotherapeutic regimens. It is known
that ATLL cells normally have chromosomal abnormalities.
These abnormalities were various types of numerical aber-
rations and complex structural abnormalities (Kamada N et
al. Cancer Res. 1992). So far only one report showed that the
impact of chromosome abnormalities for survival outcomes
in ATLL patients who received chemotherapies (Itoyama T et
al. Blood 2001). The report suggested that complex karyo-
type (more than 6 break points) abnormalities of 1p, 1q, 3q,
14q, and 17q was the poorly prognostic factors. Herewe have
analyzed the impact of chromosomal abnormalities in 26
ATLL patients who received allo-HSCT.
Seventy-two ATLL patients consecutively underwent allo-
HSCT from June 2006 to March 2014 at our center. Karyotype
study was performed with G-banding stain. Since patients’
chromosomal study showed normal karyotype and/or bad
proliferation or no information about chromosomal study, 46
of 72 patients were excluded from this study. The rest of 26
patients (13 male, 13 female) were eligible for this study.
Themedian age of patients was 54 years (34-65). All patients,
except one lymphoma type patient, were diagnosed as acute
type ATLL. Thirteen of 26 patients were performed unrelated
BMT, 8 sibling-BMT, 2 sibling PBSCT and 3 UCB. Eighteen
patients used MAC regimens and 8 RIC regimens. With
respect to disease status at allo-HSCT, 6 patients were in CR,
and 20 non-CR. Specimen materials were from 11 PB, 8 BM,
6 lymph node and 1 pleural effusion, respectively. The
median number of numerally chromosomal abnormalities
was 2 (0-10), and the median number of structural abnor-
mality was 4 (0-12), respectively. The majorities of numeral
abnormalities were defects of sex chromosomes (31%), -14
(24%) and -10 (17%), etc. Structurally, more than 6 break
points of the chromosomal abnormalities were seen in 11
patients. Majorities of structural abnormalities were abnor-
malities of 14q (41%), 1q (28%), 4q (28%) and 7q (28%), etc.
The median study observation days was 173 days (12-2895)
and an overall survival (OS) was 40.7%. Statistically, no im-
pacts were seen in chromosomal abnormality of more than 6
break points (HR:1.839, 95%CI: 0.67-5.04, P¼0.237), abnor-
malities of 1q (HR: 2.035, 95%CI: 0.718-5.77, P¼0.182), 3q
(HR: 1.1, 95%CI: 0.312-3.88, P¼0.882), 14q (HR: 1.516, 95%CI:0.565-4.07, P¼0.409) and any other chromosomal abnor-
malities with OS. Also, no statistical impacts were seen in
these chromosomal abnormalities with relapse rate and non-
relapse mortality after allo-HSCT, respectively.
Although relatively a small number study, the results newly
showed that allo-HSCT would have a potential to overcome
the poor prognostic risks in chromosomal abnormalities.84
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Background: Two recent retrospective analyses suggested
that a combination of busulfan (Bu) andMel (Bu-Mel) may be
associated with a longer progression-free survival (PFS)
compared to Mel alone. In this randomized phase III trial we
compared the safety and efﬁcacy of Bu-Mel vs. Mel.
Methods: Patients were randomized to either Bu-Mel or Mel
using the Pocock-Simon method. In the Bu-Mel arm, Bu
130 mg/m2 was infused daily for 4 days, followed by 2 daily
doses of Mel at 70 mg/m2. Mel 200 mg/m2 was given as a
single dose in the Mel only arm. The primary endpoint was
Day 90 CR (IMWG criteria) rate.
Results: Ninety-two patients (Bu-Mel: 49, Mel: 43) were
enrolled from October 2011 to August 2013. Median ages at
auto-HCT were 58.4 and 58.5 years in Bu-Mel and Mel arms,
respectively (p¼0.75). Ten (20%) and 11 (26%) patients had
high-risk chromosomal abnormalities in Bu-Mel vs. Mel,
respectively (p¼0.62). Forty-four (90%) and 40 (93%) patients
received bortezomib-based induction therapy in the Bu-Mel
and Mel, respectively (p¼0.71). At the time of auto-HCT,
8/0 (16%) and 7/3 (23%) patients were in CR/near (n)CR in Bu-
Mel and Mel arms, respectively (p¼0.44), Grade 3 non-he-
matologic toxicity was seen in 41 (84%) and 20 (47%) patients
in Bu-Mel and Mel, respectively (p¼0.0003). There was no
100-day TRM in either arm. At day 90, 8 (16%) and 15 (35%)
patients had achieved a CR (p¼0.05), and 13 (27%) and 20
(47%) patients had achieved a CR + nCR (p¼0.05) in Bu-Mel
and Mel, respectively. At day 90, 7/7 (100%) evaluable pa-
tients with CR in Bu-Mel and 14/15 (93%) evaluable patients
with CR in Mel also achieved a multiparametric ﬂow cyto-
metric (MFC) CR (p¼1.00). Thirty-nine (80%) patients in
Bu-Mel and 37 (86%) in Mel received maintenance therapy
after day 90 (p¼0.58). Median follow up was 15.7 months
(range 0.8 e 28.7). No second primary malignancies have
been seen in either arm so far. Bayesian multivariable
lognormal survival time regression showed signiﬁcantly
better PFS in the Bu-Mel arm (posterior probability of the
treatment effect >0.9963, 95% credible interval 0.21-1.70,
Figure 1). Median PFS fromDay 90was not reached in the Bu-
Mel arm. Median PFS from Day 90 for Mel only was 20
months. One-year survival rates in the Bu-Mel vs Mel arms
were 91% (95% CI: 75-97%) and 77% (95% CI: 58-88%),
Figure 1. PFS from Day 90 by Treatment Arm.
Table 1
Patient Characteristics
Median Range
Age (years) 57 32-75
N %
Sex
F 17 24
M 53 76
Conditioning regimen
2 Gy TBI 4 6
2 Gy TBI + Auto 4 6
2 Gy TBI + Flu 30 mg/m2 x 3 55 79
2 Gy TBI + Flu 30 mg/m2 x 3 + Rituxan 5 7
2 Gy TBI + Rituxan 2 3
Donor type
HLA matched related 33 47
HLA matched unrelated 29 41
HLA 1 antigen mismatched 8 11
GVHD prophylaxis
Cyclosporine/MMF 49 70
Cyclosporine/MMF/Rapamycin 2 3
Tacrolimus/MMF 15 21
Tacrolimus/MMF/Rapamycin 4 6
HCTCI
0 12 17
1- 2 26 37
> 3 30 43
Number of prior regimens
1 - 2 15 21
3 - 4 27 39
5 - 6 16 23
>7 12 17
Previous autologous transplant
Failed 28 40
Tandem auto/allo 7 10
No 35 50
Disease status at HCT
CR 26 37
PR 19 27
Relapsed/Refractory 25 36
Bulky lymphadenopathy (5 cm or >)
Y 12 17
N 58 83
CMV risk
High 38 54
Intermediate 8 11
Low 24 34
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was conducted when 65 patients were evaluable, and at that
time the Mel only arm was determined to be superior. The
study was, therefore, stopped early by the Institutional
DSMB. However, with a longer follow up Bu-Mel ultimately
resulted in better PFS.
Conclusions: Bu-Mel was associated with a signiﬁcantly
lower day 90 CR rate and a signiﬁcantly higher rate of grade
3-4 non-hematologic toxicity, compared to Mel. However,
after a median follow up of 15.7 months, PFS was signiﬁ-
cantly longer in the Bu-Mel arm.
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Previous studies have shown that a subset of patients with
relapsed Mantle cell lymphoma (MCL) beneﬁt from non-
myeloablative allogeneic hematopoietic stem cell transplant
(HCT), but literature is lacking regarding their long-term
outcomes. We examined long-term survivals, resolution of
chronic graft-versus-host-disease, and predictive factors in a
large group of patients with MCL.Seventy MCL patients, age 32 to 75 yrs, were conditioned
with 2 Gy TBI alone or combined with ﬂudarabine +/- rit-
uximab followed by HCT from related (n¼35) or unrelated
(n¼35) donors. Table 1 summarizes patient and transplant-
related characteristics. Proportional hazards models were
used to estimate the hazards of relapse or mortality after
adjustment for known risk variables.
After a median follow-up of 7.1 (0.2-12.8) yrs, 34 patients
were alive, 30 in continued remission and 4 after salvage
therapies given for progression (n¼1) or relapse (n¼3). The
5-yr incidence of non-relapse mortality (NRM) for all 70
patients was 28%. The 5-yr rate of relapse was 26%, while
those of overall (OS) and disease-free survival (DFS) were
55% and 46%, respectively (Figure 1). Among 33 pts with
sufﬁcient follow-up, 10-yr NRM, relapse, OS and DFS rates
were 41%, 18%, 44% and 41%, respectively.
Eighty percent of surviving patients were off immunosup-
pression at last follow-up, with a median time to cessation of
35 (range 1-95) months. Among the 34 surviving patients, the
median Karnofsky performance status at last contact was 90%.
Relapsed/refractory disease at time of HCT predicted a higher
rate of relapse (HR 2.94, P¼0.05) but not OS at 5 (51% versus
58%, p¼0.29) or 10 yrs (43% versus 45%, p¼0.89). High-risk
